Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 14/20 | 0.74 |
| ▸ | BCHE | P06276 | 12/20 | 0.74 |
| ▸ | GRIN1 | Q05586 | 8/20 | 0.74 |
| ▸ | GRIN2A | Q12879 | 8/20 | 0.74 |
| ▸ | MAPT | P10636 | 2/20 | 0.68 |
| ▸ | POLB | P06746 | 2/20 | 0.67 |
| ▸ | RECQL | P46063 | 1/20 | 0.67 |
| ▸ | CASP6 | P55212 | 1/20 | 0.67 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.67 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.67 |
| ▸ | GAA | P10253 | 1/20 | 0.62 |
| ▸ | TSHR | P16473 | 1/20 | 0.62 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.56 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.56 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2126156 | 0.97 | ACHE (0.74) | ACHEBCHEGRIN1GRIN2AMAPT | |
| SCHEMBL18065461 | 0.95 | ACHE (0.73) | ACHEBCHEGRIN1GRIN2AMAPT | |
| SCHEMBL4266767 | 0.87 | ACHE (0.74) | ACHEBCHEGRIN1GRIN2AMAPT | |
| SCHEMBL8006170 | 0.85 | ACHE (1.00) | ACHEBCHEGRIN1GRIN2ACHRM1 | |
| SCHEMBL29818080 | 0.84 | BCHE (0.77) | ACHEBCHEMAPTSLC2A1 | |
| SCHEMBL31442668 | 0.84 | ACHE (0.70) | ACHEBCHEGRIN1GRIN2AMAPT | |
| Hydrochloric Acid SCHEMBL29817811 | 0.84 | ACHE (1.00) | ACHEBCHEGRIN1GRIN2ACHRM1 | |
| SCHEMBL29023229 | 0.84 | ACHE (0.73) | ACHEBCHEGRIN1GRIN2AMAPT | |
| SCHEMBL5467926 | 0.83 | BCHE (0.70) | ACHEBCHEGRIN1GRIN2AMAPT | |
| SCHEMBL31139195 | 0.83 | BCHE (0.70) | ACHEBCHEGRIN1GRIN2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8765940-B2 | Heterocyclic compounds and their uses | AMGEN INC. (US) | 2014-07-01 | — | — | US | disclosed |
| US-8765940-B2 | Heterocyclic compounds and their uses | AMGEN INC. (US) | 2014-07-01 | — | — | US | disclosed |
| US-8765940-B2 | Heterocyclic compounds and their uses | AMGEN INC. (US) | 2014-07-01 | — | — | US | disclosed |
| EP-2445902-A2 | HETEROCYCLIC COMPOUNDS AND THEIR USES AS INHIBITORS OF PI3K ACTIVITY | Amgen, Inc (US) | 2012-05-02 | — | — | EP | disclosed |
| US-20120094972-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2012-04-19 | — | — | US | disclosed |
| US-20120094972-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2012-04-19 | — | — | US | disclosed |
| US-20120094972-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2012-04-19 | — | — | US | disclosed |
| WO-2010151737-A2 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2010-12-29 | — | — | WO | disclosed |
| WO-2010151737-A2 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2010-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120094972-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | MCL1, MALT1, BCL9 | ACHE 3061/4885BCHE 1616/4885GRIN1 2955/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.